^
Association details:
| Biomarker: | TNFRSF17 expression |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | JNJ-5322 (CD3 agonist, BCMA inhibitor, GPRC5D inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
456 Characterization of JNJ-79635322, a Novel BCMAxGPRC5DxCD3 T-Cell Redirecting Trispecific Antibody, for the Treatment of Multiple Myeloma
Published date:
11/02/2023
Excerpt:
JNJ-79635322 induced potent cytotoxicity in various myeloma cell lines in vitro with concomitant T-cell activation. Importantly, JNJ-79635322 was able to deplete both dual (BCMA and GPRC5D) and single (BCMA or GPRC5D) target expressing cells efficiently.... In vivo, JNJ-79635322 exhibited potent antitumor activity compared to vehicle and antibody controls in a murine MM xenograft prevention model (single target expressing clonal H929 cells) and two tumor regression models (RPMI 8226 and MM.1S cells).
